5 Dividend Aristocrats Primed For a Big 2024 ptasha / iStock via Getty Images Since 1926, dividends have accounted for almost a third of the total return of the S&P 500, so regardless of whether the market is up, down, or flat, regular dividend payments from high-quality blue chip stocks provide investors with a much better chance for success. With inflation staying frustratingly steady and the potential for more stock market turbulence in 2024, looking at quality stocks that pay dependable quarterly divi ...

Pharmaceutical company AbbVie (ABBV 0.42%) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.The company is transitioning after losing patent protection for its top-selling drug Humira, which drove the years of growth that benefited shareholders. AbbVie has shown encouraging signs, but the stock has been flat over the past year.Is AbbVie poised to regain its spark, or is the stock's epic run ending?AbbVi ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Collaboration to leverage Umoja's VivoVecTM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE, Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's propriet ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

The latest trading session saw AbbVie (ABBV) ending at $160.46, denoting a +0.4% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily loss of 0.8%. Elsewhere, the Dow lost 0.76%, while the tech-heavy Nasdaq lost 1.18%.Coming into today, shares of the drugmaker had gained 10.55% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 3.4%.The upcoming earnings release of AbbVie will be of great interest to investors. It is antic ...

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.The good news for income investors is that several great stocks on the market continue to steadily increase their dividend payouts. Here are three top dividend growth stocks to buy in 2024.1. AbbVieWith a dividend yield of 4%, AbbVie (ABBV 0.14%) certainly attracts the attention of many income investors. However, that juicy yield doesn't tell the ful ...

Ирина Мещерякова Foreword As supplement to this article, please note that The Motley Fool, which sourced this latest list, and SureDividend both update their lists periodically. While most of this collection of 54 Kings is too pricey to justify their skinny dividends, five of the top-ten, by yield, and three more outside of the top ten, live up to the ideal of offering annual dividends (from a $1K investment) exceeding their single share prices, and this month there are four more to watch. In the curren ...

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.When it was clear a few years ago that biosimilars for AbbVie's (ABBV 1.54%) Humira would be hitting the market, management knew it had work to do. Humira is the best-selling prescription drug in history, putting AbbVie on the map. But nothing lasts forever, and the company began taking steps to ensure its future success.First, AbbVie completed the bloc ...

As the new year beckons, the pharmaceutical industry is poised for more developments, building on advances made in 2023. The industry harbors several companies leading the way in groundbreaking innovations, drug discoveries, pending approvals, and market advancements, an element likely to affect their stock price positively. Indeed, some key players will likely stand out in 2024 as they are backed by critical fundamentals that are likely to drive their stocks to higher valuations. In this regard, Finbold ha ...